Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17454028rdf:typepubmed:Citationlld:pubmed
pubmed-article:17454028lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:17454028lifeskim:mentionsumls-concept:C0235032lld:lifeskim
pubmed-article:17454028lifeskim:mentionsumls-concept:C0030020lld:lifeskim
pubmed-article:17454028lifeskim:mentionsumls-concept:C1707455lld:lifeskim
pubmed-article:17454028lifeskim:mentionsumls-concept:C0470187lld:lifeskim
pubmed-article:17454028lifeskim:mentionsumls-concept:C0521116lld:lifeskim
pubmed-article:17454028lifeskim:mentionsumls-concept:C0086728lld:lifeskim
pubmed-article:17454028lifeskim:mentionsumls-concept:C0062699lld:lifeskim
pubmed-article:17454028pubmed:issue2lld:pubmed
pubmed-article:17454028pubmed:dateCreated2007-4-24lld:pubmed
pubmed-article:17454028pubmed:abstractTextThe neuroprotective effects of newly developed oximes (K074, K075) and currently available oximes (obidoxime, HI-6) in combination with atropine in rats poisoned with soman were studied. The soman-induced neurotoxicity was monitored using a functional observational battery at 24 h and 7 days after soman challenge. The results indicate that the oxime HI-6 combined with atropine seems to be an effective antidote for a decrease in soman-induced neurotoxicity, whereas the ability of both newly developed oximes (K074, K075) as well as obidoxime to counteract soman-induced acute neurotoxicity is negligible. Due to the absence of their neuroprotective potency, both newly developed oximes are not suitable oximes for antidotal treatment after exposure to soman. The oxime HI-6 is still the best acetylcholinesterase reactivator for the antidotal treatment of acute poisonings with soman.lld:pubmed
pubmed-article:17454028pubmed:languageenglld:pubmed
pubmed-article:17454028pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17454028pubmed:citationSubsetIMlld:pubmed
pubmed-article:17454028pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17454028pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17454028pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17454028pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17454028pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17454028pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17454028pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17454028pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17454028pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17454028pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17454028pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17454028pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17454028pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17454028pubmed:statusMEDLINElld:pubmed
pubmed-article:17454028pubmed:issn0148-0545lld:pubmed
pubmed-article:17454028pubmed:authorpubmed-author:KassaJiriJlld:pubmed
pubmed-article:17454028pubmed:authorpubmed-author:KarasovaJanaJlld:pubmed
pubmed-article:17454028pubmed:issnTypePrintlld:pubmed
pubmed-article:17454028pubmed:volume30lld:pubmed
pubmed-article:17454028pubmed:ownerNLMlld:pubmed
pubmed-article:17454028pubmed:authorsCompleteYlld:pubmed
pubmed-article:17454028pubmed:pagination117-31lld:pubmed
pubmed-article:17454028pubmed:meshHeadingpubmed-meshheading:17454028...lld:pubmed
pubmed-article:17454028pubmed:meshHeadingpubmed-meshheading:17454028...lld:pubmed
pubmed-article:17454028pubmed:meshHeadingpubmed-meshheading:17454028...lld:pubmed
pubmed-article:17454028pubmed:meshHeadingpubmed-meshheading:17454028...lld:pubmed
pubmed-article:17454028pubmed:meshHeadingpubmed-meshheading:17454028...lld:pubmed
pubmed-article:17454028pubmed:meshHeadingpubmed-meshheading:17454028...lld:pubmed
pubmed-article:17454028pubmed:meshHeadingpubmed-meshheading:17454028...lld:pubmed
pubmed-article:17454028pubmed:meshHeadingpubmed-meshheading:17454028...lld:pubmed
pubmed-article:17454028pubmed:meshHeadingpubmed-meshheading:17454028...lld:pubmed
pubmed-article:17454028pubmed:meshHeadingpubmed-meshheading:17454028...lld:pubmed
pubmed-article:17454028pubmed:meshHeadingpubmed-meshheading:17454028...lld:pubmed
pubmed-article:17454028pubmed:meshHeadingpubmed-meshheading:17454028...lld:pubmed
pubmed-article:17454028pubmed:meshHeadingpubmed-meshheading:17454028...lld:pubmed
pubmed-article:17454028pubmed:meshHeadingpubmed-meshheading:17454028...lld:pubmed
pubmed-article:17454028pubmed:meshHeadingpubmed-meshheading:17454028...lld:pubmed
pubmed-article:17454028pubmed:meshHeadingpubmed-meshheading:17454028...lld:pubmed
pubmed-article:17454028pubmed:meshHeadingpubmed-meshheading:17454028...lld:pubmed
pubmed-article:17454028pubmed:meshHeadingpubmed-meshheading:17454028...lld:pubmed
pubmed-article:17454028pubmed:meshHeadingpubmed-meshheading:17454028...lld:pubmed
pubmed-article:17454028pubmed:meshHeadingpubmed-meshheading:17454028...lld:pubmed
pubmed-article:17454028pubmed:year2007lld:pubmed
pubmed-article:17454028pubmed:articleTitleA comparison of the potency of newly developed oximes (K074, K075) and currently available oximes (obidoxime, HI-6) to counteract soman-induced neurotoxicity in rats.lld:pubmed
pubmed-article:17454028pubmed:affiliationDepartment of Toxicology, Faculty of Military Health Sciences, Hradec Kralove, Czech Republic. kassa@pmfhk.czlld:pubmed
pubmed-article:17454028pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17454028pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:17454028pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed